Premium
Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma
Author(s) -
Sakai Hideki,
Shiraishi Kazutaka,
Minami Yuzo,
Yushita Yoshiaki,
Kanetake Hiroshi,
Saito Yutaka
Publication year - 1991
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990190307
Subject(s) - immunostaining , prostatic acid phosphatase , medicine , immunohistochemistry , pathology , carcinoma , prostate , cancer , biopsy , adenocarcinoma , carcinoma in situ , stage (stratigraphy) , anatomical pathology , prostate cancer , oncology , biology , paleontology
To determine whether prostatic acid phosphatase (PAP) immunoreactivity in prostatic adenocarcinoma is a reliable prognostic factor, the PAP immunohistochemical distribution has been examined in 78 prostatic carcinoma cases. The intensity of PAP immunostaining was graded from 0 to 2, and the scores of the primary and the secondary staining patterns were added to assess the extent of the PAP expression in needle biopsy specimens. As a result, a higher cancer‐specific survival rate was observed in patients showing a greater PAP immunostaining ( P <0.01). Further, a multivariate analysis was made of possible prognostic factors (age, stage, Gleason score, serum PAP, PAP‐immunostaining score, and the initial treatment) to estimate the extent of their impact on cancer‐specific survival. Results have confirmed that the difference in PAP immunoreactivity is an excellent, independent prognostic factor for prostatic carcinoma.